Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor‑positive advanced breast cancer that progressed on prior endocrine therapy: A meta‑analysis-Reference-Cited by-同舟云学术

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor‑positive advanced breast cancer that progressed on prior endocrine therapy: A meta‑analysis

Published:2022-07-18 Issue:3 Volume:24 Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Xu Liang¹,Jiang Weifan²,Li Wenwei³,Guo Chungen³,Luo Lihua³,Gao Yufeng⁴,Cao Yali³

Affiliation:

1. Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang City, Nanchang, Jiangxi 330009, P.R. China

2. Department of Urinary Surgery, The Second Affiliated Hospital, Nanchang University School of Medicine, Nanchang, Jiangxi 330006, P.R. China

3. Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang City, Nanchang, Jiangxi 330009, P.R. China

4. Medical Department, Graduate School of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Reference36 articles.

1. Cancer Statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Overcoming endocrine resistance in breast cancer;Hanker;Cancer Cell,2020

3. Endocrine and targeted therapy for hormone-receptor-positive, HER2-Negative advanced breast cancer: Insights to sequencing treatment and overcoming resistance based on clinical trials;El Sayed;Front Oncol,2019

4. Clinical challenges in the management of hormone receptor-positive, human epidermal growth factor receptor 2-Negative metastatic breast cancer: A literature review;Nagaraj;Adv Ther,2021

5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial;Baselga;Lancet Oncol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resveratrol-Exemestane Beneficial Regimen to Overcome the Complications over Existing Therapies for the Management of Breast Cancer;Current Molecular Medicine;2024-02

2. Transdermal therapeutic systems in breast cancer therapy;Journal of Drug Delivery Science and Technology;2023-12

3. Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis;Cancers;2022-12-11